Lattuca, Benoit
Cayla, Guillaume
Silvain, Johanne
Cuisset, Thomas
Leclercq, Florence
Manzo-Silberman, Stephane
Saint-Etienne, Christophe
Delarche, Nicolas
El Mahmoud, Rami
Carrié, Didier
Souteyrand, Géraud
Kerneis, Mathieu
Hauguel-Moreau, Marie
Zeitouni, Michel
Guedeney, Paul
Diallo, Abdourahmane
Collet, Jean-Philippe
Vicaut, Eric
Montalescot, Gilles
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial
https://doi.org/10.1007/s40256-021-00468-8
Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study
https://doi.org/10.1016/j.ahj.2014.07.026
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
https://doi.org/10.1016/s0140-6736(16)31323-x
Article History
Accepted: 7 February 2021
First Online: 30 June 2021
Declarations
:
: The ANTARCTIC trial was conducted by the non-profit academic research organization Allies in Cardiovascular Trials, Initiatives, and Organized Networks (ACTION, ExternalRef removed). There was no specific funding for this sub-study, but the ANTARCTIC trial was supported by Eli Lilly and Company, Daiichi Sankyo, Stentys, Accriva Diagnostics, Medtronic, and <i>Fondation Coeur et Recherche</i>.
: B. Lattuca has received research grants from Biotronik, Daiichi-Sankyo, Medtronic, <i>Fédération Française de Cardiologie</i>, and Institute of Cardiometabolism and Nutrition, and expert witness fees from AstraZeneca, Daiichi-Sankyo, Eli Lilly, and Novartis. G. Cayla reports grants from <i>Fondation Coeur et Recherche</i>, Daiichi Sankyo, and Medtronic; expert witness fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Biotronik, Boston Scientific, Bristol-Myers Squibb, Eli Lilly, Europa, MSD, Pfizer, Sanofi, and The Medicines Company. J. Silvain has received research grants from Amed, Amgen, Algorythm, AstraZeneca, Bayer, CSL Behring, Daiichi-Sankyo, Eli Lilly, <i>Fondation de France</i>, Gilead Science, Iroko Cardio, Sanofi-Aventis, and Saint-Jude Medical. F. Leclercq has received research grants from Bayer, Boehringer-Ingelheim, Medtronic, and Edwards Lifesciences. S. Manzo-Silberman has received research grants from Abbott, Abiomed, AstraZeneca, Bayer, Biosensor, Biotronik, Boston-Scientific, Daiichi-Sankyo, Eli Lilly, <i>Fédération Française de Cardiologie</i>, and Novartis and expert witness fees from AstraZeneca, Biotronik, Novartis, Servier, and Terumo. M. Zeitouni has received research grants from <i>Fédération Française de Cardiologie</i> and <i>Institut Servier</i>. M. Kerneis has received research grants from <i>Fédération Française de Cardiologie</i>, European Society of Cardiology, and Servier and expert witness fees from AstraZeneca, Bayer, Daiichi-Sankyo, Eli-Lilly, and Sanofi. J.P. Collet has received research grants from AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eli-Lilly, Fédération Française de Cardiologie, Lead-Up, Medtronic, MSD, Sanofi-Aventis, and WebMD. E. Vicaut has received research grants from Boehringer and Sanofi and expert witness fees from Abbott, Eli Lilly, Fresenius, Hexacath, LFB, Medtronic, Novartis, Pfizer, and Sanofi. G. Montalescot has received research grants from Abbott, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, Axis-Santé, Bayer, Boston-Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, China Heart House, Daiichi-Sankyo, Idorsia, Elsevier, Europa, <i>Fédération Française de Cardiologie</i>, Institute of Cardiometabolism and Nutrition, Lead-Up, Medtronic, Menarini, MSD, Novo-Nordisk, Partners, Pfizer, Quantum Genomics, Sanofi, Servier, and WebMD. The other authors report no relationships that could be construed as a conflict of interest.
: The protocol was approved by the French National Institutional Ethical Review Board and complied with the Declaration of Helsinki. Informed written consent was obtained for all the patients, and the ANTARCTIC trial was monitored by an independent data and safety monitoring board. The protocol of the ANTARCTIC trial was registered on the ClinicalTrials.gov platform with the following unique identifier: NCT01538446.
: Anonymized data and materials that support the findings of this study are available from the corresponding author upon reasonable request.
: All the co-authors have approved this final submitted version and have participated substantially to this work. <i>Conception and design of the work</i>: BL, GC, JPC, EV, and GM. <i>Acquisition of the data</i>: BL, GC, JS, TC, FL, SM-S, CS-E, ND, REM, DC, GS, MK, MH-M, MZ, and PG. <i>Analysis and interpretation of the data</i>: BL, GC, AD, EV, and GM. <i>Drafting of the manuscript</i>: BL and GC. <i>Critical revision of the manuscript for important intellectual content</i>: BL, GC, EV, and GM.